Advanced search
Publication Cover
Infection and Drug Resistance Volume 11, 2018 - Issue
Submit an article Journal homepage
297
Views
67
CrossRef citations to date
0
Altmetric
Review

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae

Lindsay A Petty1 Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USACorrespondence[email protected]
,
Oryan Henig1 Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA
,
Twisha S Patel2 Department of Pharmacy Services, University of Michigan Hospitals and Health Centers, Ann Arbor, MI, USA
,
Jason M Pogue3 Department of Pharmacy Services, Sinai-Grace Hospital, Detroit Medical Center, Detroit, MI, USA
&
Keith S Kaye1 Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA
Pages 1461-1472 | Published online: 12 Sep 2018

Citations (67)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (12)

Jenna Adams, Maressa Santarossa, Amanda Harrington, Michael Bauer, Amy Wozniak, Laurie Labuszewski & Fritzie S. Albarillo. (2023) In vitro susceptibility of carbapenem resistant Enterobacterales to meropenem-vaborbactam and ceftazidime-avibactam at a single academic medical centre. Infectious Diseases 55:4, pages 282-291.
Read now
Mona Abd El-Aziz Gadallah, Wasila Moursy El-sayed, Mohammed Zakaria Hussien, Mohammed Ahmed Elheniedy & Sara Youssef Maxwell. (2023) In-vitro activity of plazomicin, meropenem-vaborbactam, and omadacycline against carbapenem-resistant Gram-negative isolates in Egypt. Journal of Chemotherapy 35:3, pages 205-218.
Read now
Rafael Canton, Yohei Doi & Patricia J. Simner. (2022) Treatment of carbapenem-resistant Pseudomonas aeruginosa infections: a case for cefiderocol. Expert Review of Anti-infective Therapy 20:8, pages 1077-1094.
Read now
Federica Romanelli, Stefania Stolfa, Anna Morea, Luigi Ronga, Raffaele Del Prete, Maria Chironna, Luigi Santacroce & Adriana Mosca. (2021) Meropenem/vaborbactam Activity In Vitro: A New Option for Klebsiella Pneumoniae Carbapenemase (KPC)-Producing Klebsiella Pneumoniae Treatment. Future Microbiology 16:16, pages 1261-1266.
Read now
Joseph P. Lynch$suffix/text()$suffix/text(), Nina M. Clark & George G. Zhanel. (2021) Escalating antimicrobial resistance among Enterobacteriaceae: focus on carbapenemases. Expert Opinion on Pharmacotherapy 22:11, pages 1455-1474.
Read now
Paulina Paprocka, Bonita Durnaś, Angelika Mańkowska, Karol Skłodowski, Grzegorz Król, Magdalena Zakrzewska, Michał Czarnowski, Patrycja Kot, Kamila Fortunka, Stanisław Góźdź, Paul B Savage & Robert Bucki. (2021) New β-Lactam Antibiotics and Ceragenins – A Study to Assess Their Potential in Treatment of Infections Caused by Multidrug-Resistant Strains of Pseudomonas aeruginosa. Infection and Drug Resistance 14, pages 5681-5698.
Read now
Jorge Reyes, Ana Cristina Aguilar & Andrés Caicedo. (2019) Carbapenem-Resistant Klebsiella pneumoniae: Microbiology Key Points for Clinical Practice. International Journal of General Medicine 12, pages 437-446.
Read now
Richard J Vickers, Matteo Bassetti, Cornelius J Clancy, Kevin W Garey, David E Greenberg, Minh-Hong Nguyen, David Roblin, Glenn S Tillotson & Mark H Wilcox. (2019) Combating Resistance While Maintaining Innovation: The Future of Antimicrobial Stewardship. Future Microbiology 14:15, pages 1331-1341.
Read now
Joseph S Solomkin, Angie Sway, Kenneth Lawrence, Melanie Olesky, Sergey Izmailyan & Larry Tsai. (2019) Eravacycline: A New Treatment Option for Complicated Intra-Abdominal Infections in the Age of Multidrug Resistance. Future Microbiology 14:15, pages 1293-1308.
Read now
Yi-Chyi Lai, Min-Chi Lu & Po-Ren Hsueh. (2019) Hypervirulence and carbapenem resistance: two distinct evolutionary directions that led high-risk Klebsiella pneumoniae clones to epidemic success. Expert Review of Molecular Diagnostics 19:9, pages 825-837.
Read now
Sebastiano Leone, Marco Cascella, Ilaria Pezone & Marco Fiore. (2019) New antibiotics for the treatment of serious infections in intensive care unit patients. Current Medical Research and Opinion 35:8, pages 1331-1334.
Read now
Debapriya Mohanty, Mrutyunjay Suar & Sandeep Kumar Panda. Nanotechnological interventions in bacteriocin formulations – advances, and scope for challenging food spoilage bacteria and drug-resistant foodborne pathogens. Critical Reviews in Food Science and Nutrition 0:0, pages 1-18.
Read now

Articles from other publishers (55)

R. Justin Grams, Webster L. Santos, Ion Romulus Scorei, Antonio Abad-García, Carol Ann Rosenblum, Andrei Bita, Hugo Cerecetto, Clara Viñas & Marvin A. Soriano-Ursúa. (2024) The Rise of Boron-Containing Compounds: Advancements in Synthesis, Medicinal Chemistry, and Emerging Pharmacology. Chemical Reviews 124:5, pages 2441-2511.
Crossref
Julianne Yeary, Larissa Hacker & Stephen Y. Liang. (2024) Managing Antimicrobial Resistance in the Emergency Department. Emergency Medicine Clinics of North America.
Crossref
Tsegaye Melaku Kebede. 2023. Urinary Tract Infections - New Insights. Urinary Tract Infections - New Insights.
Abdul Musawer Bayan, Sayed Hussain Mosawi, Najmeh Fani, Mohammad Sayed Behrad, Ahmad Jamshid Mehrpoor, Muhammad Younis Noori, Rafiullah Shirzadi, Ahmad Siar Popalzai & Fahim Amirkhezi. (2023) Integrating molecular docking and molecular dynamics simulation studies on the affinity and interactions of piperine with β-lactamase class A enzymes. Journal of Molecular Structure 1292, pages 136151.
Crossref
Miriam Stegemann & Ulrike Trost. (2023) Neue Entwicklungen in der Bekämpfung bakterieller InfektionenNew developments in the fight against bacterial infections. Die Innere Medizin 64:11, pages 1123-1128.
Crossref
Ines Zollner-Schwetz & Elisabeth König. (2023) Treatment options for multidrug-resistant Gram-negatives in urinary tract infections. Current Opinion in Urology 33:3, pages 173-179.
Crossref
Varshaa Arer & Debasish Kar. (2023) Biochemical exploration of β-lactamase inhibitors. Frontiers in Genetics 13.
Crossref
Oluwaseun Ola Adeniji, Nolonwabo Nontongana, Janet Chiyem Okoh & Anthony Ifeanyi Okoh. (2022) The Potential of Antibiotics and Nanomaterial Combinations as Therapeutic Strategies in the Management of Multidrug-Resistant Infections: A Review. International Journal of Molecular Sciences 23:23, pages 15038.
Crossref
Maria Helena Rigatto, Fabiano Ramos, Andressa Barros, Silvia Pedroso, Isabelli Guasso, Luciana Gonçalves, Pedro Bergo & Alexandre P Zavascki. (2022) Double-, single- and none-carbapenem-containing regimens for the treatment of carbapenem-resistant Enterobacterales (CRE) bloodstream infections: a retrospective cohort. Journal of Antimicrobial Chemotherapy 77:11, pages 3118-3125.
Crossref
Nikol Kaderabkova, Manasa Bharathwaj, R. Christopher D. Furniss, Diego Gonzalez, Tracy Palmer & Despoina A.I. Mavridou. (2022) The biogenesis of β-lactamase enzymes. Microbiology 168:8.
Crossref
Alain Philippon, Guillaume Arlet, Roger Labia & Bogdan I. Iorga. (2022) Class C β-Lactamases: Molecular Characteristics. Clinical Microbiology Reviews 35:3.
Crossref
Jinhua Lan, Zheng Wu, Xipei Wang, Yifan Wang, Fen Yao, Bo-xin Zhao, Yirong Wang, Jingchun Chen & Chunbo Chen. (2022) Population Pharmacokinetics Analysis and Dosing Simulations Of Meropenem in Critically Ill Patients with Pulmonary Infection. Journal of Pharmaceutical Sciences 111:6, pages 1833-1842.
Crossref
Paolo Gaibani, Tommaso Giani, Federica Bovo, Donatella Lombardo, Stefano Amadesi, Tiziana Lazzarotto, Marco Coppi, Gian Maria Rossolini & Simone Ambretti. (2022) Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing. Antibiotics 11:5, pages 628.
Crossref
Takumi Umemura, Hideo Kato, Mao Hagihara, Jun Hirai, Yuka Yamagishi & Hiroshige Mikamo. (2022) Efficacy of Combination Therapies for the Treatment of Multi-Drug Resistant Gram-Negative Bacterial Infections Based on Meta-Analyses. Antibiotics 11:4, pages 524.
Crossref
Mical Paul, Elena Carrara, Pilar Retamar, Thomas Tängdén, Roni Bitterman, Robert A. Bonomo, Jan de Waele, George L. Daikos, Murat Akova, Stephan Harbarth, Celine Pulcini, José Garnacho-Montero, Katja Seme, Mario Tumbarello, Paul Christoffer Lindemann, Sumanth Gandra, Yunsong Yu, Matteo Bassetti, Johan W. Mouton, Evelina Tacconelli & Jesús Rodríguez-Baño. (2022) European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clinical Microbiology and Infection 28:4, pages 521-547.
Crossref
Béla Kocsis, Dániel Gulyás & Dóra Szabó. (2021) Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline. Antibiotics 10:12, pages 1506.
Crossref
Alessia Savoldi, Elena Carrara, Laura J. V. Piddock, Francois Franceschi, Sally Ellis, Margherita Chiamenti, Damiano Bragantini, Elda Righi & Evelina Tacconelli. (2021) The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies. BMC Infectious Diseases 21:1.
Crossref
Clement Yaw Effah, Emmanuel Kwateng Drokow, Clement Agboyibor, Shaohua Liu, Emmanuel Nuamah, Tongwen Sun, Lijun Miao, Jing Wang, Zhiwei Xu, Yongjun Wu & Xiaoju Zhang. (2021) Evaluation of the Therapeutic Outcomes of Antibiotic Regimen Against Carbapenemase-Producing Klebsiella pneumoniae: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology 12.
Crossref
James A. Dowell, Daniel Dickerson & Tim Henkel. (2021) Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor. Antimicrobial Agents and Chemotherapy 65:11.
Crossref
Davide Carcione, Claudia Siracusa, Adela Sulejmani, Valerio Leoni & Jari Intra. (2021) Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical Use. Antibiotics 10:8, pages 995.
Crossref
Shu-Chen Kuo, Yung-Chih Wang, Mei-Chen Tan, Wei-Cheng Huang, Yih-Ru Shiau, Hui-Ying Wang, Jui-Fen Lai, I-Wen Huang & Tsai-Ling Lauderdale. (2021) In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan . Journal of Antimicrobial Chemotherapy 76:8, pages 2071-2078.
Crossref
Dipti Lai, Sumit Ghosh & Alakananda Hajra. (2021) Light-induced borylation: developments and mechanistic insights. Organic & Biomolecular Chemistry 19:20, pages 4397-4428.
Crossref
Marco Terreni, Marina Taccani & Massimo Pregnolato. (2021) New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives. Molecules 26:9, pages 2671.
Crossref
Andrew F. Shorr & Marya D. Zilberberg. (2021) Novelty and nuance in the intensive care unit: new options to combat multidrug resistant pneumonia. Current Opinion in Infectious Diseases 34:2, pages 151-155.
Crossref
Anna N. Tevyashova & Mikhail V. Chudinov. (2021) Progress in the medicinal chemistry of organoboron compounds. Russian Chemical Reviews 90:4, pages 451-487.
Crossref
Elena Xu, David Pérez-Torres, Paraskevi C. Fragkou, Jean-Ralph Zahar & Despoina Koulenti. (2021) Nosocomial Pneumonia in the Era of Multidrug-Resistance: Updates in Diagnosis and Management. Microorganisms 9:3, pages 534.
Crossref
Amanda M. Roy, MacGregor Hodgson, Cristina BrickmanConan MacDougall. (2021) Cefiderocol as Adjunctive Treatment of Necrotizing Ventilator-associated Pneumonia Due to Extensively Drug-Resistant Pseudomonas aeruginosa. Infectious Diseases in Clinical Practice 29:2, pages e111-e113.
Crossref
Geneva M Wilson, Margaret Fitzpatrick, Kyle Walding, Beverly Gonzalez, Marin L Schweizer, Katie J Suda & Charlesnika T Evans. (2021) Meta-analysis of Clinical Outcomes Using Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam for the Treatment of Multidrug-Resistant Gram-Negative Infections. Open Forum Infectious Diseases 8:2.
Crossref
Shigeru Kohno, Hiroyuki Bando, Fumihiko Yoneyama, Hiroaki Kikukawa, Kazuya Kawahara, Masayoshi Shirakawa, Norihiro Aoyama, Michelle Brown, Amanda Paschke & Akiko Takase. (2021) The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study. Journal of Infection and Chemotherapy 27:2, pages 262-270.
Crossref
Aun Raza, Shih Chen Ngieng, Fekade Bruck Sime, Peter J. Cabot, Jason A. Roberts, Amirali Popat, Tushar Kumeria & James R. Falconer. (2021) Oral meropenem for superbugs: challenges and opportunities. Drug Discovery Today 26:2, pages 551-560.
Crossref
Robert W. Finberg & Roy GuharoyRobert W. Finberg & Roy Guharoy. 2021. Clinical Use of Anti-infective Agents. Clinical Use of Anti-infective Agents 51 55 .
Gregory Snell, Olivia Smibert & Elizabeth Tullis. 2021. Emerging Transplant Infections. Emerging Transplant Infections 391 408 .
Marco Fiore, Sveva Di Franco, Aniello Alfieri, Maria Beatrice Passavanti, Maria Caterina Pace, Stephen Petrou, Francesca Martora & Sebastiano Leone. (2020) Spontaneous bacterial peritonitis due to carbapenemase-producing Enterobacteriaceae : Etiology and antibiotic treatment . World Journal of Hepatology 12:12, pages 1136-1147.
Crossref
Christopher Longshaw, Davide Manissero, Masakatsu Tsuji, Roger Echols & Yoshinori Yamano. (2020) In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe . JAC-Antimicrobial Resistance 2:3.
Crossref
Yuhang Wang, Jin Wang, Rui Wang & Yun Cai. (2020) Resistance to ceftazidime–avibactam and underlying mechanisms. Journal of Global Antimicrobial Resistance 22, pages 18-27.
Crossref
Shivakumar S. Jalde & Hyun Kyung Choi. (2020) Recent advances in the development of β-lactamase inhibitors. Journal of Microbiology 58:8, pages 633-647.
Crossref
. (2019) Newer Antibiotics: Need for More Studies in Neonates and Children. Pediatric Infectious Disease 1:4, pages 164-168.
Crossref
David M. P. De Oliveira, Brian M. Forde, Timothy J. Kidd, Patrick N. A. Harris, Mark A. Schembri, Scott A. Beatson, David L. Paterson & Mark J. Walker. (2020) Antimicrobial Resistance in ESKAPE Pathogens. Clinical Microbiology Reviews 33:3.
Crossref
Ismael Mora-Guzmán, Ines Rubio-Perez, Rocío Maqueda González, Diego Domingo Garcia & Elena Martín-Pérez. (2020) Infección de sitio quirúrgico asociada a enterobacterias productoras de carbapenemasas. Un desafío para el cirujano actual. Cirugía Española 98:6, pages 342-349.
Crossref
Ismael Mora-Guzmán, Ines Rubio-Perez, Rocío Maqueda González, Diego Domingo Garcia & Elena Martín-Pérez. (2020) Surgical Site Infection by Carbapenemase-producing Enterobacteriaceae: A Challenge for Today's Surgeons. Cirugía Española (English Edition) 98:6, pages 342-349.
Crossref
Anna N. Tevyashova. (2020) Oxaborine Derivatives: Synthesis and Therapeutic Potential. Chemistry of Heterocyclic Compounds 56:6, pages 715-718.
Crossref
Li-Chin Lu, Chih-Cheng Lai, Shen-Peng Chang, Shao-Huan Lan, Shun-Hsing Hung & Wei-Ting Lin. (2020) Novel β-Lactam/β-Lactamase inhibitor combinations vs alternative antibiotics in the treatment of complicated urinary tract infections. Medicine 99:19, pages e19960.
Crossref
Afroza Akhtar, Orville A. Pemberton & Yu Chen. (2019) Structural Basis for Substrate Specificity and Carbapenemase Activity of OXA-48 Class D β-Lactamase. ACS Infectious Diseases 6:2, pages 261-271.
Crossref
Kalyani Borde, P Swathi & Dilip Mathai. (2020) Lateral flow assay for the rapid detection of carbapenemases in Enterobacterales. Journal of The Academy of Clinical Microbiologists 22:2, pages 85.
Crossref
Zifang Shang, Siew Yin Chan, Qing Song, Peng Li & Wei Huang. (2020) The Strategies of Pathogen-Oriented Therapy on Circumventing Antimicrobial Resistance. Research 2020.
Crossref
Yih Chyn Phan & Bob Yang. 2020. Female Urinary Tract Infections in Clinical Practice. Female Urinary Tract Infections in Clinical Practice 29 38 .
Gregory Snell, Olivia Smibert & Elizabeth Tullis. 2019. Emerging Transplant Infections. Emerging Transplant Infections 1 19 .
Hanan Haydar, Ethan Leonard & Ankita Desai. (2019) New and Emerging Infections: a Select Review of Evolving Pathogens. Current Treatment Options in Pediatrics 5:3, pages 284-292.
Crossref
Suay-García & Pérez-Gracia. (2019) Present and Future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections. Antibiotics 8:3, pages 122.
Crossref
Cornelius J Clancy, Brian A Potoski, Deanna Buehrle & M Hong Nguyen. (2019) Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data. Open Forum Infectious Diseases 6:8.
Crossref
Petrosillo, Taglietti & Granata. (2019) Treatment Options for Colistin Resistant Klebsiella pneumoniae: Present and Future. Journal of Clinical Medicine 8:7, pages 934.
Crossref
Sebastiano Leone, Giovanni Damiani, Ilaria Pezone, Molly E. Kelly, Marco Cascella, Aniello Alfieri, Maria C. Pace & Marco Fiore. (2019) New antimicrobial options for the management of complicated intra-abdominal infections. European Journal of Clinical Microbiology & Infectious Diseases 38:5, pages 819-827.
Crossref
Bo Gao, Xiandong Li, Fengmei Yang, Wei Chen, Ying Zhao, Gang Bai & Zhaoyong Zhang. (2019) Molecular Epidemiology and Risk Factors of Ventilator-Associated Pneumonia Infection Caused by Carbapenem-Resistant Enterobacteriaceae. Frontiers in Pharmacology 10.
Crossref
Chau-Chyun Sheu, Ya-Ting Chang, Shang-Yi Lin, Yen-Hsu Chen & Po-Ren Hsueh. (2019) Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options. Frontiers in Microbiology 10.
Crossref
Courtney L Luterbach, Ashley Boshe, Heather I Henderson, Eric Cober, Sandra S Richter, Robert A Salata, Robert C Kalayjian, Richard R Watkins, Andrea M Hujer, Kristine M Hujer, Susan D Rudin, T Nicholas Domitrovic, Yohei Doi, Keith S Kaye, Scott Evans, Vance G FowlerJr.Jr., Robert A Bonomo & David van Duin. (2019) The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae. Open Forum Infectious Diseases 6:1.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.